Karen Bush

Q: What Schools Are Affiliated With Karen Bush

Karen Bush is affiliated with the following schools: Monmouth College, University of the Balearic Islands, University of California, Berkeley, Indiana University Bloomington, Indiana University, Stanford University

Karen Bush's AcademicInfluence.com Rankings

Karen Bush

Biology

#5181

World Rank

#7605

Historical Rank

Biochemistry

#717

World Rank

#817

Historical Rank

biology Degrees

Download Badge

Biology

Karen Bush's Degrees

Bachelors Biochemistry University of California, Berkeley

Why Is Karen Bush Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Karen Bush is an American biochemist. She is a professor of Practice in Biology at Indiana University and the interim director of the Biotechnology program. Bush conducts research focusing on bacterial resistance mechanisms to beta-lactam antibiotics.

(See a Problem?)

Karen Bush's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A functional classification scheme for beta-lactamases and its correlation with molecular structure (1995) (2706)
Carbapenemases: the Versatile β-Lactamases (2007) (2041)
Updated Functional Classification of β-Lactamases (2009) (1642)
Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae (2001) (1288)
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase (2006) (934)
Tackling antibiotic resistance (2011) (653)
Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae (2008) (620)
Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. (1999) (543)
β-Lactams and β-Lactamase Inhibitors: An Overview. (2016) (498)
Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein (1997) (480)
New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. (2001) (441)
Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. (2011) (418)
Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. (2010) (409)
Past and Present Perspectives on β-Lactamases (2018) (345)
Carbapenem-hydrolyzing beta-lactamases (1997) (340)
Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria (1982) (291)
Proliferation and significance of clinically relevant β‐lactamases (2013) (289)
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. (2003) (266)
Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. (1996) (261)
Monocyclic β-lactam antibiotics produced by bacteria (1981) (259)
Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses (2001) (257)
Characterization of beta-lactamases (1989) (248)
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes (1993) (243)
Epidemiology of β-Lactamase-Producing Pathogens (2020) (240)
Interplay between β-lactamases and new β-lactamase inhibitors (2019) (235)
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. (2008) (234)
LactamasesFunctional Classification of (2010) (233)
Metallo-β-Lactamases: A Class Apart (1998) (211)
Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae (1996) (210)
Carbapenem-Resistant Strain of Klebsiella oxytoca Harboring Carbapenem-Hydrolyzingβ -Lactamase KPC-2 (2003) (205)
The ABCD’s of β-lactamase nomenclature (2013) (203)
Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae (1989) (202)
Classification of beta-lactamases: groups 1, 2a, 2b, and 2b' (1989) (201)
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients (1992) (196)
Bench-to-bedside review: The role of β-lactamases in antibiotic-resistant Gram-negative infections (2010) (178)
Beta-lactamase inhibitors from laboratory to clinic (1988) (172)
Multiple Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-Component Systems (1999) (165)
Antimicrobial resistance in anaerobes. (1997) (163)
Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae (2007) (152)
Effects of Inoculum and β-Lactamase Activity in AmpC- and Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates Tested by Using NCCLS ESBL Methodology (2004) (152)
Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate (1994) (152)
Critical analysis of antibacterial agents in clinical development (2020) (147)
A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. (2015) (147)
Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. (2002) (145)
First Nosocomial Outbreak of Pseudomonas aeruginosa Producing an Integron-Borne Metallo-β-Lactamase (VIM-2) in the United States (2005) (143)
Extended-spectrum β-lactamases in North America, 1987–2006 (2008) (142)
Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. (2000) (138)
SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients (1995) (135)
SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens Strains (2000) (128)
Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4 (1989) (123)
Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. (1995) (120)
Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants (1994) (119)
Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria (1982) (119)
Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae (1985) (119)
Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa (2008) (116)
Improving known classes of antibiotics: an optimistic approach for the future. (2012) (106)
Hydrolysis and Inhibition Profiles of β-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem (2009) (103)
Crystal structure of the wide-spectrum binuclear zinc β-lactamase from Bacteroides fragilis (1996) (103)
Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. (1991) (101)
In Vitro Susceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations (2014) (101)
The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors (2000) (100)
Taking inventory: antibacterial agents currently at or beyond phase 1. (2004) (99)
New β-lactam antibiotics and β-lactamase inhibitors (2010) (99)
Investigational Antimicrobial Agents of 2013 (2013) (97)
Antimicrobial resistance in Bacteroides. (1993) (96)
Antibacterial drug discovery in the 21st century. (2004) (95)
Identification and Characterization of New Inhibitors of the Escherichia coli MurA Enzyme (2001) (94)
Nomenclature of TEM beta-lactamases. (1997) (87)
Monobactams—monocyclic β -lactam antibiotics produced by bacteria (1981) (85)
Biochemical characterization of the metallo-beta-lactamase CcrA from Bacteroides fragilis TAL3636 (1992) (84)
Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. (2012) (83)
Carbapenemases: Partners in crime. (2013) (82)
Antimicrobial agents targeting bacterial cell walls and cell membranes. (2012) (81)
Cloning and expression of a cloxacillin-hydrolyzing enzyme and a cephalosporinase from Aeromonas sobria AER 14M in Escherichia coli: requirement for an E. coli chromosomal mutation for efficient expression of the class D enzyme (1994) (80)
Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects (2007) (80)
Extended-spectrum beta-lactamases in North America, 1987-2006. (2008) (79)
Interactions of Ceftobiprole with β-Lactamases from Molecular Classes A to D (2007) (78)
How β-Lactamases Have Driven Pharmaceutical Drug Discovery (1998) (78)
Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae (1994) (76)
Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. (1999) (75)
Methodology for the study of beta-lactamases (1986) (74)
beta-Lactamases of increasing clinical importance. (1999) (69)
Prevalence of Single Mutations in Topoisomerase Type II Genes among Levofloxacin-Susceptible Clinical Strains of Streptococcus pneumoniae Isolated in the United States in 1992 to 1996 and 1999 to 2000 (2002) (69)
CAU-1, a Subclass B3 Metallo-β-Lactamase of Low Substrate Affinity Encoded by an Ortholog Present in the Caulobacter crescentus Chromosome (2002) (68)
Effective Antimicrobial Regimens for Use in Humans for Therapy of Bacillus anthracis Infections and Postexposure Prophylaxis (2005) (67)
In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum Fluoroquinolone (2010) (67)
Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy (2007) (66)
Epidemiology and Risk Factors for Isolation of Escherichia coli Producing CTX-M-Type Extended-Spectrum β-Lactamase in a Large U.S. Medical Center (2013) (64)
Recent developments in beta-lactamase research and their implications for the future. (1988) (60)
Novel antibacterial agents for the treatment of serious Gram-positive infections. (2003) (60)
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles (2017) (59)
Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Isolates Producing TEM-10 and TEM-43 β-Lactamases from St. Louis, Missouri (1998) (56)
Outbreak of Ceftazidime Resistance Due to a Novel Extended-Spectrum β-Lactamase in Isolates from Cancer Patients (1993) (55)
Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences (1993) (55)
Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? (2014) (54)
Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). (2003) (54)
Muraceins--muramyl peptides produced by Nocardia orientalis as angiotensin-converting enzyme inhibitors. I. Taxonomy, fermentation and biological properties. (1984) (53)
Biochemical Characterization of β-Lactamases Bla1 and Bla2 from Bacillus anthracis (2003) (53)
b -Lactams and b -Lactamase Inhibitors: An Overview (2016) (51)
The impact of beta-lactamases on the development of novel antimicrobial agents. (2002) (51)
New antimicrobial agents on the horizon. (2011) (51)
SME-3, a Novel Member of the Serratia marcescens SME Family of Carbapenem-Hydrolyzing β-Lactamases (2006) (49)
Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. (1989) (49)
Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey Model (2006) (49)
Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check. (2015) (49)
Is it necessary to change the classification of β-lactamases? (2005) (48)
Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam (2017) (48)
β-Lactamase inhibitors in perspective (1983) (48)
New agents in development for the treatment of bacterial infections. (2008) (47)
Game Changers: New β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria. (2017) (46)
A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. (2003) (45)
Nomenclature of TEM-lactamases (45)
Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of beta-lactams in three Bacteroides fragilis isolates that harbor a metallo-beta-lactamase gene (1994) (43)
Crystal structures of the cadmium‐ and mercury‐substituted metallo‐β‐lactamase from Bacteroides fragilis (1997) (43)
In vitro activity of plazomicin against &bgr;-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) (2017) (42)
Cloning and Biochemical Characterization of FOX-5, an AmpC-Type Plasmid-Encoded β-Lactamase from a New York CityKlebsiella pneumoniae Clinical Isolate (2001) (42)
Activities of Ceftobiprole and Other β-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x (2006) (42)
Impact of Different Carbapenems and Regimens of Administration on Resistance Emergence for Three Isogenic Pseudomonas aeruginosa Strains with Differing Mechanisms of Resistance (2010) (42)
β-Lactamase Nomenclature (2005) (41)
Why It Is Important To Continue Antibacterial Drug Discovery Combating resistance, improving safety, and preserving R&D teams are among reasons for persevering (2004) (41)
Oral Administration of Cyclopentane Neuraminidase Inhibitors Protects Ferrets against Influenza Virus Infection (2002) (40)
Is it important to identify extended-spectrum beta-lactamase-producing isolates? (1996) (40)
The coming of age of antibiotics: discovery and therapeutic value (2010) (39)
SQ 26,180, a novel monobactam. I Taxonomy, fermentation and biological properties. (1982) (39)
New approaches in the treatment of bacterial infections. (2000) (39)
Biochemical characterization of the carbapenem-hydrolyzing beta-lactamase AsbM1 from Aeromonas sobria AER 14M: a member of a novel subgroup of metallo-beta-lactamases. (1996) (39)
In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline (2016) (37)
Penicillin-binding proteins and induction of AmpC beta-lactamase (1997) (37)
Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. (2003) (37)
Two new monobactam antibiotics produced by a Flexibacter sp. I. Taxonomy, fermentation, isolation and biological properties. (1983) (37)
Pharmacodynamic Evaluation of RWJ-270201, a Novel Neuraminidase Inhibitor, in a Lethal Murine Model of Influenza Predicts Efficacy for Once-Daily Dosing (2001) (37)
Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. (2013) (36)
Metallo-beta-lactamases: a class apart. (1998) (36)
MurF Inhibitors with Antibacterial Activity: Effect on Muropeptide Levels (2009) (34)
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. (2007) (33)
Effect of MexXY Overexpression on Ceftobiprole Susceptibility in Pseudomonas aeruginosa (2009) (33)
A Standard Numbering Scheme for Class C β-Lactamases (2019) (33)
Antibacterial activity of BMS-180680, a new catechol-containing monobactam (1997) (32)
In vitro evaluation of tigemonam, a novel oral monobactam (1987) (32)
In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections (2008) (32)
SHV-7, a Novel Cefotaxime-Hydrolyzing β-Lactamase, Identified in Escherichia coli Isolates from Hospitalized Nursing Home Patients (1995) (31)
A MurF Inhibitor That Disrupts Cell Wall Biosynthesis in Escherichia coli (2007) (31)
Utility of Muropeptide Ligase for Identification of Inhibitors of the Cell Wall Biosynthesis Enzyme MurF (2006) (31)
TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases (1996) (30)
EM5400, a family of monobactam antibiotics produced by Agrobacterium radiobacter. I. Taxonomy, fermentation and biological properties. (1982) (30)
How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. (1998) (30)
β-Lactam Resistance in the 21st Century (2005) (29)
Excitement in the β-lactamase arena (1989) (29)
Bacterial enzymatic resistance: β-lactamases and aminoglycoside-modifying enzymes (1998) (29)
Properties of a class C beta-lactamase from Serratia marcescens. (1986) (28)
Two new inhibitors of phospholipase A2 produced by Penicillium chermesinum. Taxonomy, fermentation, isolation, structure determination and biological properties. (1985) (27)
Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole (2010) (27)
Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. (2007) (26)
Synthesis and release of doxorubicin from a cephalosporin based prodrug by a β-lactamase-immunoconjugate (1993) (26)
Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives. (2007) (25)
Physiology, Biochemistry, and Inactivation of β - Lactamases (1982) (24)
RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. (2001) (24)
Inhibition of herpes simplex virus type 1 DNA polymerase by the natural product oosporein. (1992) (24)
Phenacein--an angiotensin-converting enzyme inhibitor produced by a streptomycete. I. Taxonomy, fermentation and biological properties. (1984) (24)
Novel piperidinyloxy oxazolidinone antibacterial agents. Diversification of the N-Substituent. (2002) (23)
Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. (2019) (23)
In Vitro Activity of Ceftolozane-Tazobactam as Determined by Broth Dilution and Agar Diffusion Assays against Recent U.S. Escherichia coli Isolates from 2010 to 2011 Carrying CTX-M-Type Extended-Spectrum β-Lactamases (2014) (23)
Comment on: Redefining extended-spectrum beta-lactamases: balancing science and clinical need. (2009) (22)
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. (2008) (22)
Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). (2006) (22)
Antibacterial activity of pyrrolopyridine-substituted oxazolidinones: synthesis and in vitro SAR of various C-5 acetamide replacements. (2006) (22)
Monocyclic beta-lactam antibiotics produced by bacteria. (1981) (21)
Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. (2001) (21)
The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones. (2004) (21)
Improved sensitivity in assays for binding of novel beta-lactam antibiotics to penicillin-binding proteins of Escherichia coli (1987) (21)
Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes. (2005) (21)
Izumenolide-a novel beta-lactamase inhibitor produced by Micromonospora. II. Biological properties. (1980) (20)
Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones. (2009) (20)
Preparation of Erythromycin Analogs Having Functional Groups at C-15 (2006) (20)
In Vivo Activity of Ceftobiprole in Murine Skin Infections Due to Staphylococcus aureus and Pseudomonas aeruginosa (2009) (20)
In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 (2006) (19)
Inhibition of metallo-β-lactamases by pyridine monothiocarboxylic acid analogs (2010) (19)
Predominance of 23S rRNA Mutants among Non-Erm, Non-Mef Macrolide-Resistant Clinical Isolates of Streptococcus pneumoniae Collected in the United States in 1999-2000 (2005) (19)
Biochemical characteristics of extended broad spectrum β-lactamases (1989) (18)
Biochemical Characterization of Novel Tetrahydrofuranyl 1β-Methylcarbapenems: Stability to Hydrolysis by Renal Dehydropeptidases and Bacterial β-Lactamases, Binding to Penicillin Binding Proteins, and Permeability Properties (1999) (18)
β-Lactamases of Increasing Clinical Importance (1999) (18)
Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics. (2004) (18)
Cathelicidin Antimicrobial Peptides with Reduced Activation of Toll-Like Receptor Signaling Have Potent Bactericidal Activity against Colistin-Resistant Bacteria (2016) (17)
Is it necessary to change the classification of {beta}-lactamases? (2005) (17)
Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase (1991) (17)
15-Amido Erythromycins: Synthesis and in Vitro Activity of a New Class of Macrolide Antibiotics (2005) (17)
Effects of Ceftobiprole and Oxacillin on mecA Expression in Methicillin-Resistant Staphylococcus aureus Clinical Isolates (2009) (17)
The Curious Case of TEM-116 (2016) (17)
Overcoming β-lactam resistance in Gram-negative pathogens. (2016) (16)
Deuterium Effects on Binding of Reduced Coenzyme Alcohol Dehydrogenase Isoenzyme EE (1971) (16)
Vancomycin-resistant Staphylococcus aureus in the clinic: not quite armageddon. (2004) (15)
The evolution of beta-lactamases. (1997) (15)
In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 (2009) (15)
The Extended-Spectrum K1 β-Lactamase from Klebsiella oxytoca SC 10,436 Is a Member of the blaOXY-2 Family of Chromosomal Klebsiella Enzymes (2002) (15)
TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum β-Lactamase Produced by a Clinical Isolate of Klebsiella pneumoniae (2002) (15)
Interaction of New Cepbalosporins with β-Lactamases and β-Lactamase-Producing Gram-Negative Bacilli (1983) (14)
Screening and characterization of enzyme inhibitors as drug candidates. (1983) (14)
Effectiveness of fluoroquinolones against gram-positive bacteria. (2000) (14)
Monobactams--monocyclic beta-lactam antibiotics produced by bacteria. (1981) (14)
Identification of a Dithiazoline Inhibitor of Escherichia colil,d-Carboxypeptidase A (2005) (14)
Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae. (2008) (14)
Synthesis and structure-activity relationships of novel THF 1β-methylcarbapenems (1997) (13)
The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. (2000) (12)
Peptidic prodrugs of novel aminomethyl-THF 1β-methylcarbapenems (1997) (12)
Detection of multiresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins. (2000) (12)
The Importance of β-Lactamases to the Development of New β-Lactams (2009) (12)
Inhibition of Escherichia coli TEM-2 beta-lactamase by the sulfated compounds izumenolide, panosialin and sodium dodecyl sulfate. (1980) (12)
Novel piperidinyloxy oxazolidinone antimicrobial agents. (2001) (12)
Comment on: Resistance gene naming and numbering: is it a new gene or not? (2016) (12)
Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives. (2006) (12)
beta-Lactamase inhibitors in perspective. (1983) (11)
The Evolution of β‐Lactamases (2007) (11)
Amp C β-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge (2006) (11)
Synergistic Antibiotic Combinations (2017) (11)
Methodology for the Study of P-Lactamases (10)
Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy (2018) (10)
‘Superbugs’: new antibacterials in the pipeline (2000) (10)
Biochemical characteristics of extended broad spectrum beta-lactamases. (1989) (9)
Unusual carbapenem resistant but ceftriaxone and cefepime susceptible Klebsiella oxytoca isolated from a blood culture: Case report and whole-genome sequencing investigation (2017) (9)
Introduction to Antimicrobial Therapeutics Reviews: The bacterial cell wall as an antimicrobial target (2013) (9)
Bacterial enzymatic resistance: beta-lactamases and aminoglycoside-modifying enzymes. (1998) (9)
High-performance liquid chromatography of the topical anti-inflammatory steroid halcinonide (1980) (9)
CHAPTER 1 – Interaction of β-Lactam Antibiotics with β-Lactamases as a Cause for Resistance (1984) (9)
Activity of sulfa drugs and dihydrofolate reductase inhibitors againstCandida albicans (1982) (9)
Antibiotics: Synergistic MRSA combinations. (2015) (9)
Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials. (2009) (8)
Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides. (2006) (8)
Interactions of monobactams with bacterial enzymes (1987) (8)
In Vitro Activities of Novel 2-Fluoro-Naphthyridine-Containing Ketolides (2005) (8)
Introduction to Antimicrobial Therapeutics Reviews: Infectious Diseases of Current and Emerging Concern (2014) (7)
Amp C beta-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge. (2006) (7)
Cautious Optimism for the Antibacterial Pipeline: Despite dire warnings, there is resurgent effort to develop novel antibiotics, with several dozen candidate drugs already entered into clinical trials (2014) (7)
Synthesis and antibacterial activity of C6-carbazate ketolides. (2006) (7)
1-Lactamase Inhibitors fromLaboratory toClinic (1988) (6)
Novel antibacterial agents for the treatment of serious Gram-positive infections (2003) (6)
Mono and bis double ester prodrugs of novel aminomethyl-THF 1β-methylcarbapenems (1997) (6)
Excitement in the beta-lactamase arena. (1989) (6)
Oxacillin hydrolysis by the LCR-1 beta-lactamase (1995) (6)
Consensus on β-Lactamase Nomenclature (2022) (6)
Affinity of Ceftobiprole for Penicillin-Binding Protein 2b in Streptococcus pneumoniae Strains with Various Susceptibilities to Penicillin (2010) (5)
0 1-Lactamase Inhibitors from Laboratory to Clinic (5)
Evolution of β-Lactamases: Past, Present, and Future (2012) (5)
Characterization and Dynamics of Middle Ear Fluid and Nasopharyngeal Isolates of Streptococcus pneumoniae from 12 Children Treated with Levofloxacin (2007) (5)
7-(4-Alkylidenylpiperidinyl)-quinolone bacterial topoisomerase inhibitors. (2014) (5)
Inactivation of β-lactamases from Enterobacter cloacae by monophosphams (1988) (5)
Characterisation of Staphylococcus aureus and Enterococcus faecalis mutants with reduced susceptibility to the investigational oxazolidinone RWJ-416457. (2010) (4)
In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates. (2022) (4)
β-Lactam antibiotics (2010) (4)
β-Lactamases: Historical Perspectives (2007) (4)
Other β-lactam antibiotics (2011) (4)
Antibiotics and antibiotic resistance. (2016) (3)
Introduction to Antimicrobial Therapeutics Reviews (2011) (3)
The Role of Penicillin-Binding Proteins for β-Lactam Resistance in a β-Lactamase ProducingBacteroides uniformisStrain (1996) (3)
The Principles of Teaching Riding: The Official Manual of the Association of British Riding Schools (2001) (2)
Author Correction: Interplay between β-lactamases and new β-lactamase inhibitors (2019) (2)
P1321 Regional variation in Panton-Valentine leukocidin positivity smong S. aureus isolates in complicated skin and skin structure infections (2007) (2)
Casting a broader net for approaches to antibacterial research and development. Editorial overview. (2008) (2)
What do we mean by antibiotic resistance? (2004) (2)
15‐Amido Erythromycins: Synthesis and in vitro Activity of a New Class of Macrolide Antibiotics. (2005) (2)
Recent Epidemiological Changes in Infectious Diseases (2017) (1)
P2026 Activity of ceftobiprole against Pseudomonas aeruginosa clinical isolates from Europe collected in 2005–2006 (2007) (1)
The History of ICAAC: Since the first ICAAC in 1961, the meeting has grown markedly in size, scope, quality, and international breadth (2010) (1)
Identiﬁcation of a Dithiazoline Inhibitor of Escherichia coli L , D -Carboxypeptidase A (2005) (1)
Classification for β-lactamases: historical perspectives (2023) (1)
_-Lactams for the Treatment of Biofilm-Associated Infections (2005) (1)
PERINATAL/NEONATAL CASE PRESENTATION Amp C b-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge (2006) (1)
Synthesis and Structure—Activity Relationships of Novel THF 1β‐Methylcarbapenems. Part 2. (2010) (1)
A Tribute to George A. Jacoby (2022) (0)
Publisher Correction: Interplay between β-lactamases and new β-lactamase inhibitors (2019) (0)
Consequences of increasing resistance to antimicrobial agents. Discussion (1998) (0)
O120 Characteristics of complicated skin and skin structure infections due to staphylococci and the presence of Panton-Valentine leukocidin (2007) (0)
Interplay between β-lactamases and new β-lactamase inhibitors (2019) (0)
Faculty Opinions recommendation of A plasmid-borne Shewanella algae Gene, qnrA3, and its possible transfer in vivo between Kluyvera ascorbata and Klebsiella pneumoniae. (2008) (0)
Leadership in Action: Growing Great Leaders (2015) (0)
Editorial overviewAnti-infectives: Antibacterial therapies — the search continues (2006) (0)
Beta-lactamase nomenclature. (2005) (0)
Biochemical Characterization oftheMetallo-j3-Lacta mase CcrA fromBacteroides fragilis TAL3636 (1992) (0)
A Meandering Path from Biochemist to Microbiologist. (2018) (0)
Global Threat of KPC Carbapenemases (2011) (0)
Antimicrobial agents. (1997) (0)
MINIREVIEWS Characterization of r-Lactamases (0)
Afﬁnity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa (cid:1) (2008) (0)
Antibacterial Agents, Overview (2003) (0)
Mechanisms of Antibiotic Resistance in GNRs (2004) (0)
Problem Horse: An Owner's Guide (1992) (0)
MINIREVIEWS Characterization ofr-Lactamases (1989) (0)
In memoriam: John P. Quinn, MD. (2014) (0)
Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences: 356 (1416) (2001) (0)
P710 Baseline activity of ceftobiprole against methicillin-susceptible and -resistant staphylococcal clinical isolates from Europe collected in 2005–2006 (2007) (0)
Reply to Furlan et al., “Importance of Sequencing To Determine Functional blaTEM Variants” (2017) (0)
The Synthesis and SAR of Rhodanines as Novel C β-Lactamase Inhibitors. (2000) (0)
Bush Origins of antibiotic drug discovery therapy for the treatment of susceptible strains of Mycobacterium tuberculosis (2010) (0)
Publisher Correction: Interplay between β-lactamases and new β-lactamase inhibitors (2019) (0)
Critical analysis of antibacterial agents in clinical development (2020) (0)
The Genomics Approach: Is it Really the Solution? (2001) (0)
A Standard Numbering Scheme for Class C (cid:2) -Lactamases (2021) (0)
Streptogramins and Oxazolidinones (2007) (0)
Process for the preparation of novel therapeutically useful furyl and tienyylikarbapeneemijohdannaisten (1994) (0)
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles (2017) (0)
Inactivation of beta-lactamases from Enterobacter cloacae by monophosphams. (1988) (0)
Synthesis and Antibacterial Activity of C‐6 Carbamate Ketolides, a Novel Series of Orally Active Ketolide Antibiotics. (2004) (0)
Chapter 134 – β-Lactam antibiotics (2010) (0)
Faculty Opinions recommendation of Emergence of Klebsiella pneumoniae isolate co-producing NDM-1 with KPC-2 from India. (2011) (0)
Methodology fortheStudyofP-Lactamases (1986) (0)
P2025 Activity of ceftobiprole against US clinical S. pneumoniae isolates that are ceftriaxone non–susceptible (2007) (0)
Author Correction: Interplay between β-lactamases and new β-lactamase inhibitors (2019) (0)
Improved Sensitivity inAssays forBinding ofNovel3-Lactam Antibiotics toPenicillin-Bindi ng (1987) (0)
Biochemistry of beta-lactamases and penicillin-binding proteins - Discussion (1988) (0)
Faculty Opinions recommendation of Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? (2007) (0)
Differential Selection of Single-Step AmpC or Efﬂux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole (cid:1) and Chemo-therapy, (2010) (0)
Faculty Opinions recommendation of Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. (2009) (0)
Preparation of Erythromycin Analogues Having Functional Groups at C‐15. (2007) (0)
Success and Challenges Associated with Large-Scale Collaborative Surveillance for Carbapenemase Genes in Gram-Negative Bacteria (2021) (0)
656 Editorial Commentary: Ceftobiprole: A New Option for Treatment of Skin and Soft-Tissue Infections due to Methicillin-Resistant Staphylococcus aureus (2008) (0)
Comprar Antimicrobial Therapeutics Reviews | Karen Bush | 9781573317887 | Woodhead Pub (2011) (0)
Leading article Nomenclature of TEM -lactamases (1997) (0)
P2027 Ceftobiprole activity and resistance patterns in staphylococcal isolates from a recent complicated skin and skin structure infection study (2007) (0)
Discovery of Novel Antibacterial Agents: Looking Backward, Moving Ahead (2011) (0)
All New Antimicrobial Agents (2008) (0)
Recent Developments in 3-Lactamase Research and Their Implications (1988) (0)
Antibiotic resistance : Lessons for the future. Discussion (1998) (0)

This paper list is powered by the following services:

Other Resources About Karen Bush

en.wikipedia.org

What Schools Are Affiliated With Karen Bush?

Karen Bush is affiliated with the following schools:

Karen Bush's Academic­Influence.com Rankings